{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.067","upperLimit":"1.00","value":"0.33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Estimated using the Kaplan-Meier method in all cohorts.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.\n\nlenalidomide: Given PO\n\nrituximab: Given IV\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (Lenalidomide, Rituximab)"},{"description":"Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.\n\nlenalidomide: Given PO\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"Primary objective could not be completed because there were no patients enrolled in the second experimental arm (lenalidomide). Additionally, having only three patients in one arm does not allow for a meaningful comparison to historic controls.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Improvement in Overall Survival of Patients Receiving Lenalidomide With or Without Rituximab in Comparison to Historical Controls Managed by Single or Multiple Chemotherapeutic Agents or Donor Lymphocyte Infusion (DLI) (Cohort 1)","type":"PRIMARY","unitOfMeasure":"survival probability"}